Google_______________

Effects of Weight, Body Composition, and Testosterone on Bone Mineral Density in HIV Positive Women

Past studies have produced conflicting data on the prevalence of and risk factors for bone loss -- including mild osteopenia and more severe osteoporosis -- in HIV positive women.

As reported in the June 1, 2007 Journal of Acquired Immune Deficiency Syndromes, researchers from Massachusetts General Hospital and Harvard Medical School conducted a study to examine the effects of reduced androgen levels, changes in weight, body composition, and menstrual dysfunction on bone mineral density (BMD).

The study included 152 HIV positive women and 100 HIV negative control subjects. Among the HIV positive women, 124 had a normal body weight (greater than 90% ideal body weight), while 28 were low weight (90% or less of ideal body weight).

BMD was assessed using dual x-ray absorptiometry, and free testosterone was assessed by equilibrium dialysis. Abdominal subcutaneous adipose tissue and visceral adipose tissue were determined using computed tomography.

Results

A significant difference in BMD was observed between the HIV positive low weight, HIV positive normal weight, and HIV negative groups:

- lumbar spine (0.92 vs 1.01 vs 1.07 g/cm; P < 0.0001);
- total hip (0.84 vs 0.94 vs 0.98 g/cm; P < 0.0001);
- femoral neck (0.73 vs 0.83 vs 0.87 g/cm; P < 0.0001).
Among the HIV positive women, lumbar BMD correlated with:

- percentage of ideal body weight (r = 0.37; P < 0.0001);
- total body lean mass (r = 0.43; P < 0.0001);
- total body fat mass (r = 0.35; P < 0.0001);
- subcutaneous adipose tissue (r = 0.41; P < 0.0001).
However, lumbar BMD did not correlate with visceral adipose tissue (r = 0.07; P =0.417).
Among the HIV positive women, clinical risk factors for osteopenia and osteoporosis identified in a univariate analysis included:

- low free testosterone (<1.1 pg/mL, the lower limit of the normal range of free testosterone for women, or 3.8 pmol/L; P = 0.0007);
- low body weight (P = 0.014);
- sparse menstruation (P = 0.0006).
In a multivariate regression analysis, lean body mass was most significantly associated with BMD among HIV positive women.

Conclusion

In conclusion, the authors wrote, "These data demonstrate that BMD is reduced among HIV-infected women in association with low weight, reduced lean mass, reduced androgen levels, and abnormal menstrual function."

06/15/07

Reference
SE Dolan, S Carpenter, and S Grinspoon. Effects of Weight, Body Composition, and Testosterone on Bone Mineral Density in HIV-Infected Women. JAIDS 45(2): 161-167. June 1, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Index of All HIV and AIDS
Articles by Topic ( A to Z)


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)